Drugs / Fasudil
Fasudil
also known as
Fasudil Hydrochloride · AT 877 · Eril · Fasudil hydrochloride (Fasudil) · Fasudil hydrochloride hydrate · HA 1077 · NSC-759827 · WP-0512 · +1 more
Trials 15 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 212 trials | ||||||
| Phase 2 | NCT06890858 | Apr 2025 → Jan 2028 expected | ovarian cancer | Zhejiang Provincial People's Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06362707 | Aug 2024 → Jan 2028 expected | Alzheimer disease, subjective cognitive decline | Helse Stavanger HF | Recruiting | No outcome recorded |
| Phase 2 | NCT07250542 | Jul 2024 → Dec 2025 overdue | prostate cancer | baotai Liang | Recruiting | No outcome recorded |
| Phase 2 | NCT05931575 | Sep 2023 → Sep 2026 expected | Parkinson disease | Technical University of Munich | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05218668 | Dec 2021 → Jul 2026 overdue | amyotrophic lateral sclerosis | Woolsey Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04734379 | Jan 2021 → Nov 2022 | corticobasal syndrome, progressive supranuclear palsy | Woolsey Pharmaceuticals | Unknown | No outcome recorded |
| Phase 2 | NCT04793659 | Dec 2020 → Dec 2021 | dementia | Woolsey Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03792490 | Feb 2019 → Nov 2022 | amyotrophic lateral sclerosis | University Medical Center Goettingen | Completed | No outcome recorded |
| Phase 2 | NCT03404843 | Jul 2017 → Oct 2018 | cardiovascular disorder | Colorado State University | Completed | No outcome recorded |
| Phase 2 | NCT01935518 | Sep 2013 → Mar 2015 | amyotrophic lateral sclerosis | Peking University Third Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00670202 | Mar 2008 → Jan 2011 | carotid stenosis | Brigham and Women's Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT00120718 | Jun 2002 → Jan 2007 | atherosclerosis, hyperlipidemia | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06861192 | Feb 2025 → Mar 2026 overdue | prostate cancer | baotai Liang | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00498615 | Apr 2007 → Mar 2012 | Raynaud disease, scleroderma | Johns Hopkins University | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT03753269 | Jul 2019 → Jun 2022 | ST-elevation myocardial infarction | RenJi Hospital | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT04191954 Comparator | Jun → Nov 2019 | retinopathy of prematurity | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT03391219 Comparator | Jan → Apr 2018 | retinal vein occlusion | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01823081 Comparator | Jan → Jun 2013 | diabetic macular edema | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 20 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Fasudil | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06362707 ↗ |
| Known as | AT 877 | ChEMBL registry synonym — accepted as the source's own label CHEMBL38380 ↗ |
| Known as | Eril | ChEMBL registry synonym — accepted as the source's own label CHEMBL38380 ↗ |
| Known as | Fasudil Hydrochloride | “Fasudil hydrochloride combined with immunotherapy” NCT07250542 ↗3“Fasudil hydrochloride (Fasudil)” NCT05931575 ↗ “Drug: Fasudil Hydrochloride” NCT06890858 ↗ “Drug: Fasudil Hydrochloride” NCT03404843 ↗ |
| Known as | Fasudil hydrochloride (Fasudil) | “Fasudil hydrochloride (Fasudil)” NCT05931575 ↗ |
| Known as | Fasudil hydrochloride hydrate | “Fasudil (Fasudil hydrochloride hydrate IV solution) Dosage form: intravenous, application over 45 minutes” NCT03792490 ↗ |
| Known as | HA 1077 | ChEMBL registry synonym — accepted as the source's own label CHEMBL38380 ↗ |
| Known as | NSC-759827 | ChEMBL registry synonym — accepted as the source's own label CHEMBL38380 ↗ |
| Known as | WP-0512 | “Fasudil (WP-0512)” NCT05218668 ↗ |
| Known as | ZK-258594 | ChEMBL registry synonym — accepted as the source's own label CHEMBL38380 ↗ |
| Action | Inhibit | “rho kinase inhibitor” NCT00120718 ↗ |
| Modality | Small molecule | “Fasudil is a small molecule inhibitor of Rho-associated kinase (ROCK)” PMID 39424560 ↗ Nov 2024 |
| Route | Oral | “a single, oral 40 mg Fasudil dose” NCT00498615 ↗ |